NDATOPICALOINTMENT
Approved
Feb 2026
Lifecycle
Launch
Competitive Pressure
0/100
Data completeness
3/8 — Basic
ADQUEY (adquey) by Acrotech Biopharma is phosphodiesterase-4 (pde-4). First approved in 2026.
Drug data last refreshed 21h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ADQUEY (difamilast) is a topical ointment that works as a phosphodiesterase-4 (PDE-4) inhibitor, approved in February 2026. It reduces cytokine and chemokine production by increasing intracellular cyclic AMP levels, though its exact therapeutic mechanism remains incompletely defined. The product is positioned as a dermatological agent for topical use.
Launch10.7 years to LOE
Early-stage launch phase with moderate competitive pressure (18/100) suggests building commercial infrastructure and market education efforts.
Mechanism of Action
phosphodiesterase-4 (PDE-4). Difamilast’s inhibition of PDE-4 (a major cyclic adenosine monophosphate (AMP)-metabolizing enzyme) activity leads to accumulation of intracellular cyclic AMP and decreased productions of various cytokines and chemokines. However, the specific mechanism(s) by which…
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
ADQUEY represents a launch-stage opportunity with early career exposure to dermatology market dynamics and competitive positioning strategy. The compressed 5-year exclusivity window demands rapid execution, making this ideal for career growth in commercial launch and brand-building roles.
Brand Manager
Worked on ADQUEY at Acrotech Biopharma? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.